MA35611B1 - Composé inhibiteur de la signalisation par la voie notch - Google Patents

Composé inhibiteur de la signalisation par la voie notch

Info

Publication number
MA35611B1
MA35611B1 MA36712A MA36712A MA35611B1 MA 35611 B1 MA35611 B1 MA 35611B1 MA 36712 A MA36712 A MA 36712A MA 36712 A MA36712 A MA 36712A MA 35611 B1 MA35611 B1 MA 35611B1
Authority
MA
Morocco
Prior art keywords
inhibitor compound
signal inhibitor
notch route
notch
route
Prior art date
Application number
MA36712A
Other languages
English (en)
Inventor
Philip Arthur Hipskind
Gregory Alan Stephenson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA35611B1 publication Critical patent/MA35611B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne un composé, ou un sel ou hydrate pharmaceutiquement acceptable, et une composition pharmaceutique contenant ledit composé, ou sel ou hydrate pharmaceutiquement acceptable, utile en tant qu'inhibiteur de la signalisation par la voie notch pour le traitement du cancer.
MA36712A 2011-07-27 2014-01-22 Composé inhibiteur de la signalisation par la voie notch MA35611B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161512016P 2011-07-27 2011-07-27
US201161560486P 2011-11-16 2011-11-16
PCT/US2012/047100 WO2013016081A1 (fr) 2011-07-27 2012-07-18 Composé inhibiteur de la signalisation par la voie notch

Publications (1)

Publication Number Publication Date
MA35611B1 true MA35611B1 (fr) 2014-11-01

Family

ID=46598983

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36712A MA35611B1 (fr) 2011-07-27 2014-01-22 Composé inhibiteur de la signalisation par la voie notch

Country Status (36)

Country Link
US (1) US8569286B2 (fr)
EP (1) EP2736920B1 (fr)
JP (1) JP6027110B2 (fr)
KR (1) KR101578309B1 (fr)
CN (1) CN103732612B (fr)
AP (1) AP4080A (fr)
AR (1) AR087107A1 (fr)
AU (1) AU2012287251B2 (fr)
BR (1) BR112014001600B1 (fr)
CA (1) CA2841178C (fr)
CL (1) CL2014000175A1 (fr)
CO (1) CO6862159A2 (fr)
CR (1) CR20140036A (fr)
CY (1) CY1116645T1 (fr)
DK (1) DK2736920T3 (fr)
DO (1) DOP2014000011A (fr)
EA (1) EA023044B1 (fr)
EC (1) ECSP14013179A (fr)
ES (1) ES2544937T3 (fr)
GT (1) GT201400012A (fr)
HK (1) HK1194086A1 (fr)
HR (1) HRP20150771T1 (fr)
HU (1) HUE027534T2 (fr)
IL (1) IL229988A (fr)
JO (1) JO3148B1 (fr)
MA (1) MA35611B1 (fr)
ME (1) ME02171B (fr)
MX (1) MX356536B (fr)
MY (1) MY184303A (fr)
PE (1) PE20141061A1 (fr)
PL (1) PL2736920T3 (fr)
PT (1) PT2736920E (fr)
RS (1) RS54135B1 (fr)
SI (1) SI2736920T1 (fr)
TW (1) TWI568730B (fr)
WO (1) WO2013016081A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014110506A2 (fr) * 2013-01-14 2014-07-17 The Trustees Of Columbia University In The City Of New York Procédés de traitement, de prévention et de diagnostic de la leucémie et d'autres maladies et troubles sanguins
CA2938626A1 (fr) 2013-07-26 2015-01-29 John Rothman Compositions permettant d'ameliorer l'avantage therapeutique du bisantrene
TWI704151B (zh) 2014-12-22 2020-09-11 美商美國禮來大藥廠 Ｅｒｋ抑制劑
TWI609687B (zh) 2015-04-14 2018-01-01 美國禮來大藥廠 平滑肌肉瘤之標靶性治療
TWI625332B (zh) * 2015-07-07 2018-06-01 美國禮來大藥廠 刻痕（ｎｏｔｃｈ）路徑傳訊抑制化合物
CN109071504B (zh) 2016-02-05 2022-03-08 戴纳立制药公司 受体相互作用蛋白激酶1的抑制剂
IL261721B (en) 2016-03-15 2022-07-01 Oryzon Genomics Sa Combinations of lsd1 inhibitors for use in the treatment of solid tumors
KR102418765B1 (ko) * 2016-04-12 2022-07-08 일라이 릴리 앤드 캄파니 암 치료를 위한 Notch 및 CDK4/6 억제제의 조합 요법
ES2898952T3 (es) * 2016-04-12 2022-03-09 Lilly Co Eli Terapia de combinación con inhibidores de Notch y PI3K/mTOR para su uso en el tratamiento del cáncer de ovario
SG11201810268YA (en) 2016-05-20 2018-12-28 Lilly Co Eli Combination therapy with notch and pd-1 or pd-l1 inhibitors
EP3506905B1 (fr) * 2016-08-31 2024-03-20 Eli Lilly and Company Schéma posologique pour le traitement de tumeurs solides
US11376259B2 (en) 2016-10-12 2022-07-05 Eli Lilly And Company Targeted treatment of mature T-cell lymphoma
CN110383066B (zh) 2016-12-09 2023-03-31 戴纳立制药公司 化合物、组合物和方法
US11845803B2 (en) 2017-02-17 2023-12-19 Fred Hutchinson Cancer Center Combination therapies for treatment of BCMA-related cancers and autoimmune disorders
TW201932482A (zh) 2017-11-01 2019-08-16 美商奇諾治療有限公司 對b細胞成熟抗原具特異性之嵌合抗原受體及編碼聚核苷酸
JP7233425B2 (ja) * 2017-11-06 2023-03-06 ジュノー セラピューティクス インコーポレイテッド 細胞療法とガンマセクレターゼ阻害剤との組み合わせ
AU2019266150A1 (en) * 2018-05-06 2021-01-07 Ayala Pharmaceuticals Inc. Combination compositions comprising bisfluoroalkyl-1,4- benzodiazepinone compounds and methods of use thereof
MX2021003773A (es) 2018-10-02 2021-07-16 Frequency Therapeutics Inc Composiciones farmacéuticas y métodos relacionados con los agentes terapéuticos óticos.
MA55611A (fr) 2019-04-08 2022-02-16 Frequency Therapeutics Inc Association de chir99021 et d'acide valproïque pour traiter une perte auditive
AU2023206890A1 (en) 2022-01-12 2024-08-22 Denali Therapeutics Inc. Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2, 3,4,5- tetrahydropyrido [3,2-b] [l,4]oxazepin-3-yl)-4h-l,2,4-triazole-3-carboxamide

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL196641B1 (pl) * 1996-12-23 2008-01-31 Elan Pharm Inc Związki laktamowe i środek farmaceutyczny
AU4707999A (en) 1998-06-22 2000-01-10 Elan Pharmaceuticals, Inc. Compounds for inhibiting beta-amyloid peptide release and/or its synthesis
AU4710199A (en) * 1998-06-22 2000-01-10 Elan Pharmaceuticals, Inc. Compounds for inhibiting beta-amyloid peptide release and/or its synthesis
BRPI0407262A (pt) 2003-02-04 2006-01-31 Hoffmann La Roche Derivados de malonamida como inibidores gama-secretase
EP1711470B1 (fr) 2003-09-09 2009-04-15 F. Hoffmann-La Roche Ag Derives de malonamide bloquant l'activite gama-secretase
KR100867035B1 (ko) 2003-10-06 2008-11-04 에프. 호프만-라 로슈 아게 감마-세크레타제 저해제로서 유용한 치환된다이벤조-아제핀 및 벤조-다이아제핀 유도체
CA2645756C (fr) 2006-03-27 2013-12-31 F. Hoffmann-La Roche Ag Derives de malonamide en tant qu'inhibiteurs de la gamma secretase
MX2009007864A (es) * 2007-02-02 2009-07-31 Hoffmann La Roche Derivados de 6-oxo-6,7-dihidro-5h-dibenzo[b,d]azepin-7-ilo.
AU2009203776A1 (en) 2008-01-11 2009-07-16 F. Hoffmann-La Roche Ag Use of a gamma-secretase inhibitor for treating cancer
WO2011060051A1 (fr) * 2009-11-12 2011-05-19 University Of Massachusetts Méthodes de traitement du glioblastome

Also Published As

Publication number Publication date
AU2012287251B2 (en) 2015-05-14
AP2014007362A0 (en) 2014-01-31
EA201490161A1 (ru) 2014-04-30
AR087107A1 (es) 2014-02-12
CY1116645T1 (el) 2017-03-15
PE20141061A1 (es) 2014-09-06
JP6027110B2 (ja) 2016-11-16
HUE027534T2 (en) 2016-11-28
IL229988A (en) 2017-07-31
MX356536B (es) 2018-06-01
MX2014001084A (es) 2014-02-27
MY184303A (en) 2021-03-31
BR112014001600B1 (pt) 2022-09-13
SI2736920T1 (sl) 2015-08-31
ES2544937T3 (es) 2015-09-07
CO6862159A2 (es) 2014-02-10
HRP20150771T1 (hr) 2015-08-28
WO2013016081A1 (fr) 2013-01-31
CN103732612B (zh) 2015-09-23
TW201315732A (zh) 2013-04-16
EA023044B1 (ru) 2016-04-29
CL2014000175A1 (es) 2014-08-22
KR20140026624A (ko) 2014-03-05
KR101578309B1 (ko) 2015-12-16
US20130029972A1 (en) 2013-01-31
BR112014001600A2 (pt) 2017-02-21
GT201400012A (es) 2014-07-16
PT2736920E (pt) 2015-09-16
CR20140036A (es) 2014-03-21
CN103732612A (zh) 2014-04-16
ECSP14013179A (es) 2014-03-31
CA2841178C (fr) 2016-12-20
JP2014527042A (ja) 2014-10-09
RS54135B1 (en) 2015-12-31
JO3148B1 (ar) 2017-09-20
PL2736920T3 (pl) 2015-11-30
DOP2014000011A (es) 2014-07-31
AU2012287251A1 (en) 2014-01-30
EP2736920A1 (fr) 2014-06-04
CA2841178A1 (fr) 2013-01-31
DK2736920T3 (en) 2015-07-20
ME02171B (me) 2015-10-20
EP2736920B1 (fr) 2015-07-01
TWI568730B (zh) 2017-02-01
US8569286B2 (en) 2013-10-29
HK1194086A1 (en) 2014-10-10
NZ618891A (en) 2015-12-24
AP4080A (en) 2017-03-29

Similar Documents

Publication Publication Date Title
MA35611B1 (fr) Composé inhibiteur de la signalisation par la voie notch
PH12020551062A1 (en) 1,2,4-oxadiazole compounds as inhibitors of cd47 signalling pathways
MA43169B1 (fr) Composés héterocycliques en tant qu' inhibiteurs pi3k-gamma
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
MA42678B1 (fr) Nouveaux analogues nucléosidiques substitués à cycle aromatique bicyclique 6-6 pour une utilisation en tant qu'inhibiteurs de prmt5
MA37866B1 (fr) Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur
MA38227A1 (fr) Nouveaux composés bicycliques et leur utilisation en tant qu'agents antibactériens et inhibiteurs de ?-lactamase
MA51204B1 (fr) Formes pharmaceutiques comprenant un inhibiteur de la kallicréine plasmatique
MX2016017030A (es) Inhibidores de cinasa de interaccion con proteina cinasa activada por mitogeno (mnk) y metodos relacionados con los mismos.
MA37888A1 (fr) Composition pharmaceutique enrobée contenant du régorafenib
MA38472B1 (fr) Composé peptidique
MA35275B1 (fr) Composés de tétrahydropyridopyridine et tétrahydropyridopyrimidine et utilisation de ceux-ci en tant que modulateurs de récepteur c5a
EA201390908A1 (ru) Производные бицикло[3.2.1]октиламида и их применение
MA35351B1 (fr) Nouveau dérivé 1,2,3,4- tétrahydroquinoléine utile pour le traitement du diabète.
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
TN2014000016A1 (en) 4 - piperidinyl compounds for use as tankyrase inhibitors
EA201291217A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ПРОИЗВОДНЫЕ 1-(β-D-ГЛЮКОПИРАНОЗИЛ)-2-ТИЕНИЛМЕТИЛБЕНЗОЛА КАК ИНГИБИТОРЫ НЗПГ
MA47736B1 (fr) Pyrimidopyrimidinones utiles en tant qu'inhibiteurs de la kinase wee-1
MA35107B1 (fr) Composition pharmaceutique antihypertensive
MA34545B1 (fr) Co-cristaux et sels d'inhibiteurs de ccr3
MA42776B1 (fr) Composés utiles pour l'inhibition du ror-gamma-t
MA37501B1 (fr) Composés de pyrazole utilisés en tant qu'inhibiteurs de sglt1
MA38679A1 (fr) Modulateurs du récepteur de cxcr7
UA103329C2 (ru) Соли соединений-ингибиторов вич
MA40366A (fr) Dérivés de tétrahydroquinoline à titre d'inhibiteurs des bromodomaines